Zidovudine-resistant HIV strains in intravenous drug users and homosexual men in Amsterdam;ZIDOVUDINE-RESISTENTE HIV-STAMMEN BIJ INTRAVENEUZE-DRUGSGEBRUIKERS EN HOMOSEKSUELE MANNEN IN AMSTERDAM

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 17, 1996, Pages 932-934

  De Ronde, A ^a,c   De Rooij, E K ^a,c   Coutinho, R A ^b   Goudsmit, J ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c Afd Humane Retrovirologie ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DRUG ABUSE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NETHERLANDS;

COHORT STUDIES; DRUG RESISTANCE; HIV; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; POINT MUTATION; SUBSTANCE ABUSE, INTRAVENOUS; ZIDOVUDINE;

EID: 0029982163     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Portegies P, Gans J de, Lange JM, Derix MM, Speelman H, Bakker M, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989;299:819-21.
2. Everdingen JJE van, Lange JMA. Consensus vroegtijdige intervenue met zidovudine. Ned Tijdschr Geneeskd 1991;135:1547-50.
3. Boucher CA, Tersmette M, Lange JM, Kellam P, Goede RE de, Mulder JW, et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990;336:585-90.
4. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IV, et al. HIV-I RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
5. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type I. N Engl J Med 1993;328:1163-5.
6. Wahlberg J, Fiore J, Angarano G, Uhlen M, Albert J. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type I variants. J Infect Dis 1994;169:611-4.
7. Veenstra J, Schuurman R, Cornelissen M, Wout AB van 't, Boucher CAB, Schuitemaker H, et al. Transmission of zidovudine-resistant HIV-I variants following deliberate injection with blood of an AIDS patient: virus characteristics and natural history. Clin Infect Dis 1995;21:556-60.
8. Wolf F de, Goudsmit J, Paul DA, Lange JMA, Hooijkaas C, Schellekens P, et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. BMJ 1987;295:569-72.
9. Hoek JAR van den, Coutinho RA, Haastrecht HJA van, Zadelhoff AW van, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988;2:55-60.
10. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-10.
11. Nijhuis M, Boucher CAB, Schuurman R. Sensitive procedure for the amplification of HIV-I RNA using a combined reverse-transcription and amplification reaction. Biotechniques 1995;19:178-80.
12. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type I reverse transcriptase. J Gen Virol 1994;75:951-7.
13. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type I reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
14. Jong MD de, Schuurman R, Lange JMA, Boucher CAB. Absent virus load response to nevirapine due to selection of a minor preexisting drug-resistant proviral HIV-I subpopulation. Antiviral Therapy 1996;1:33-41.